Translational Drug Discovery & Molecular Design
Lucid Pharma 3DS combines medicinal chemistry expertise, molecular design technologies, and practical drug discovery experience to support pre-clinical asset generation, lead optimisation, and early therapeutic innovation.
Selected Discovery Achievements
Clinical Development Contribution – Contributed medicinal chemistry support to a therapeutic programme progressing into Phase 2 clinical studies.
Intellectual Property – Inventor on 12 patent filings spanning small molecule drug discovery and molecular design.
Biotechnology Asset Generation – Participated in discovery activities contributing to the advancement of biotechnology assets associated with company acquisition.
Drug Discovery Leadership – Experience across hit identification, hit-to-lead optimisation, lead optimisation, CRO coordination, and cross-functional discovery planning.
Services
Project proposals, analysis & consultancy
High Throughput Screening (HTS) triage & hit selection
Hit-to-lead (H2L) & Lead Optimisation (LO) phases
CRO and synthetic chemistry resource management
Synthetic route development
Medicinal chemistry data analysis
Intellectual Property (IP) protection strategies
Radianz MDE
Our propriety drug design & discovery algorithm: Radianz MDE (Molecular Design Engine)
Radianz MDE was created on the principles of medicinal chemistry excellence: pharmacophore analysis, pharmacokinetics and synthetic chemistry.
